Lensar System Receives FDA Clearance

Facebook X LinkedIn Email
Ocular laser developer Lensar Inc. has received 510(k) clearance from the U.S. FDA for its LENSAR laser system with Streamline IV, expanding the platform’s capabilities to include the creation of the corneal pockets and flaps used in ophthalmic procedures treating presbyopia.

With the new indications, the LENSAR laser system now supports surgeons offering the latest presbyopic inlay devices to patients struggling with the loss of near vision due to aging.

“The continued expansion of capabilities with the LENSAR laser system is the latest demonstration of our commitment to technological innovation that serves surgeons pursuing excellent visual outcomes for their patients,” said Nicholas Curtis, CEO of Lensar. “Lensar’s technology is known for its adaptability and high-quality treatment capability. It made sense to evolve our platform to support surgeons meeting the increasing patient demand with options for the treatment of presbyopia with corneal inlay devices.”

The presbyopia procedure features of the LENSAR laser system with Streamline IV include a new curved contact patient interface device that enables the creation of corneal pockets and flaps without compromising patient comfort.

Published: April 2018
BusinessLensarU.S. Food and Drug AdministrationLensar Laser SystemStreamline IVAmericasBiophotonicsRapidScan

We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.